May 8, 2020 / 6:57 AM / 18 days ago

BRIEF-Karolinska Development's Portfolio Company Umecrine Cognition Presents Positive Additional Results From Phase 2A Study Of Golexanolone

May 8 (Reuters) - Karolinska Development AB:

* REG-KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY UMECRINE COGNITION PRESENTS POSITIVE ADDITIONAL RESULTS FROM A PHASE 2A STUDY OF GOLEXANOLONE

* PORTFOLIO COMPANY UMECRINE COGNITION HAS PRESENTED POSITIVE SUPPLEMENTARY RESULTS FROM A PHASE 2A STUDY OF GOLEXANOLONE

* TOP-LINE DATA FROM PHASE 2A STUDY OF GOLEXANOLONE IN PATIENTS WITH LIVER CIRRHOSIS AND MILD HEPATIC ENCEPHALOPATHY (HE) WAS PRESENTED IN APRIL 2020

* SUBJECTS IN ALL TREATMENT GROUPS SHOWED DIRECTIONALLY FAVORABLE IMPROVEMENTS IN COGNITIVE FUNCTION

* UMECRINE COGNITION WILL REVISIT DEVELOPMENT STRATEGY FOR GOLEXANOLONE, IN ORDER TO OPTIMIZE VALUE OF ITS DRUG CANDIDATE BASED ON THESE ENCOURAGING FINDING Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below